Healthcare resource utilization and costs associated with non-adherence to imatinib treatment in chronic myeloid leukemia patients

References

• Fialkow PJ, Jacobson RJ, Papayannopoulou T. Chronic myelocytic leukemia: clonal origin in a stem cell common to the granulocyte, erythrocyte, platelet and monocyte/macrophage. Am J Med 1977;63:125-30
   PubMed Web of Science ®Google Scholar
• Kalidas M, Kantarjian H, Talpaz M. Chronic myelogenous leukemia. JAMA 2001;286:895-8
   PubMed Web of Science ®Google Scholar
• Surveillance, Epidemiology and End Results, SEER. Median age of cancer patients at diagnosis. SEER Cancer Statistics Review 1975-2006, Accessed online at http://seer.cancer.gov/csr/1975_2006/results_single/sect_01_table.11_2pgs.pdf. last accessed on 6/12/09
   Google Scholar
• Faderl S, Talpaz M, Estrov Z, et al. Chronic myelogenous leukemia: biology and therapy. Ann Intern Med 1999;131:207-19
   PubMed Web of Science ®Google Scholar
• Cortes J, Baccarani M, Guilhot F, et al. A phase III, randomized, open-label study of 400 mg versus 800 mg of imatinib mesylate in patients with newly diagnosed, previously untreated chronic myeloid leukemia in chronic phase using molecular endpoints: 1-year results of TOPS (Tyrosine Kinase Inhibitor Optimization and Selectivity) study. American Society of Hematology Annual Meeting, December 2008
   Google Scholar
• Nowell PC, Hungerford DA. Chromosome studies on normal and leukemic human leukocytes. J Natl Cancer Inst 1960;25:85-109
   PubMed Web of Science ®Google Scholar
• Rowley JD. Letter: A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. Nature 1973;243:290-3
   PubMed Web of Science ®Google Scholar
• Ben-Neriah Y, Daley GQ, Mes-Masson AM, et al. The chronic myelogenous leukemia-specific P210 protein is the product of the bcr/abl hybrid gene. Science 1986;233:212-14
   PubMed Web of Science ®Google Scholar
• Sokal JE. Prognosis in chronic myeloid leukaemia: biology of the disease vs. treatment. Baillieres Clin Haematol 1987;1:907-29
   PubMedGoogle Scholar
• Kantarjian HM, Dixon D, Keating MJ, et al. Characteristics of accelerated disease in chronic myelogenous leukemia. Cancer 1988;61:1441-6
   PubMed Web of Science ®Google Scholar
• Fabian MA, Biggs WH, Treiber DK, et al. A small molecule-kinase interaction map for clinical kinase inhibitors. Nat Biotechnol 2005;23:329-36
   PubMed Web of Science ®Google Scholar
• Druker BJ, Tamura S, Buchdunger E, et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 1996;2:561-6
   PubMed Web of Science ®Google Scholar
• Druker BJ, Talpaz M, Resta DJ, et al. Efficacy and safety of a specific inhibitor of the bcr-abl tyrosine kinase in chronic myeloid leukemia. N Eng J Med 2001; 344:1031-7
   PubMed Web of Science ®Google Scholar
• Talpaz M, Silver RT, Druker BJ, et al. Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study. Blood 2002;99:1928-37
   PubMed Web of Science ®Google Scholar
• Kantarjian HM, Cortes J, O’Brien S, et al. Imatinib mesylate (STI571) therapy for Philadelphia chromosome-positive chronic myelogenous leukemia in blast phase. Blood 2002;99:3547-53
   PubMed Web of Science ®Google Scholar
• Horner MJ, Ries LAG, Krapcho M, et al. (eds). SEER Cancer Statistics Review, 1975-2006, National Cancer Institute. Bethesda, MD, based on November 2008 SEER data submission, posted to the SEER web site, 2009. Accessed online at http://seer.cancer.gov/csr/1975_2006, last accessed on 6/12/09
   Google Scholar
• Lahaye T, Riehm B, Berger U, et al. Response and resistance in 300 patients with BCR-ABL-positive leukemias treated with imatinib in a single center: a 4.5-year follow-up. Cancer 2005;103:1659-69
   PubMed Web of Science ®Google Scholar
• O’Brien S, Berman E, Bhalla K, et al. NCCN Clinical Practice Guidelines in Oncology: Chronic Myelogenous Leukemia: National Comprehensive Cancer Network, 2007
   Google Scholar
• O’Brien SG, Guilhot F, Druker BJ, et al. The IRIS study in early chronic phase CML: 7 year follow-up. American Society of Hematology Annual Meeting, December 2008
   Google Scholar
• Hochhaus A, O’Brian SG, Guilhot F, et al. Six-year follow-up of patients receiving imatinib for first-line treatment of chronic myeloid leukemia. Leukemia 2009 March 12
   Google Scholar
• Picard S, Titier K, Etienne G, et al. Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia. Blood 2007;109:3496-9
   PubMed Web of Science ®Google Scholar
• Shenolikar RA, Balkrishnan R, Camacho FT, et al. Comparison of medication adherence and associated health care costs after introduction of pioglitazone treatment in African Americans versus all other races in patients with type 2 diabetes mellitus: a retrospective data analysis. Clin Ther 2006;28:1199-207
   PubMed Web of Science ®Google Scholar
• Lee WC, Balu S, Cobden D, et al. Prevalence and economic consequences of medication adherence in diabetes: a systematic literature review. Manag Care Interface 2006;19:31-41
   PubMedGoogle Scholar
• Sokol MC, McGuigan KA, Verbrugge RR, et al. Impact of medication adherence on hospitalization risk and healthcare cost. Med Care 2005;43:521-30
   PubMed Web of Science ®Google Scholar
• Partridge AH, Wang PS, Winer EP, et al. Nonadherence to adjuvant tamoxifen therapy in women with primary breast cancer. J Clin Oncol 2003;21:602-6
   PubMed Web of Science ®Google Scholar
• Partridge AH, Avorn J, Wang PS, et al. Adherence to therapy with oral antineoplastic agents. J Natl Cancer Inst 2002;94:652-61
   PubMed Web of Science ®Google Scholar
• Sandoval C, Giamelli J, Jayabose S. Imatinib mesylate noncompliance simulating chronic myeloid leukemia resistance. J Pediatr Hematol Oncol 2003;25:507-8
   PubMed Web of Science ®Google Scholar
• Doti C, Stemmelin G, Shanley C. Cytogenetic response in relation to the adherence to treatment with imatinib mesylate: a case control study. Blood (ASH Annual Meeting Abstracts) 2007;110:Abstract 4553
   Web of Science ®Google Scholar
• Noens L, van Lierde MA, De Bock R, et al. Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: the ADAGIO study. Blood 2009;113:5401-11
   PubMed Web of Science ®Google Scholar
• Baccarani M, Martinelli G, Rosti G, et al. Imatinib and pegylated human recombinant interferon-alpha2b in early chronic-phase chronic myeloid leukemia. Blood 2004;104:4245-51
   PubMed Web of Science ®Google Scholar
• Cervantes F, Hernandez-Boluda JC, Steegmann JL, et al. Imatinib mesylate therapy of chronic phase chronic myeloid leukemia resistant or intolerant to interferon: results and prognostic factors for response and progression-free survival in 150 patients. Haematologica 2003;88:1117-22
   PubMed Web of Science ®Google Scholar
• Kantarjian H, Sawyers C, Hochhaus A, et al. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med 28 2002;346:645-52
   PubMed Web of Science ®Google Scholar
• Mills EJ, Nachega JB, Buchan I, et al. Adherence to antiretroviral therapy in sub-Saharan Africa and North America: a meta-analysis. JAMA. 2006;296:679-90
   PubMed Web of Science ®Google Scholar
• Demissie S, Silliman RA, Lash TL. Adjuvant tamoxifen: Predictors of use, side effects, and discontinuation in older women. J Clin Oncol 2001;19:322-8
   PubMed Web of Science ®Google Scholar
• Fink AK, Gurwitz J, Rakowski W, et al. Patient beliefs and tamoxifen discontinuance in older women with estrogen receptor-positive breast cancer. J Clin Oncol 2004;22:3309-3315
   PubMed Web of Science ®Google Scholar
• Lash TL, Fox MP, Westrup JL, et al. Adherence to tamoxifen over the five-year course. Breast Cancer Res Treat 2006;99:215-20
   PubMed Web of Science ®Google Scholar
• Ziller V, Kalder M, Albert US, et al. Adherence to adjuvant endocrine therapy in postmenopausal women with breast cancer. Ann Oncol 2009;20:431-6
   PubMed Web of Science ®Google Scholar
• Darkow T, Henk HJ, Thomas, SK, et al. Treatment interruptions and non-adherence with imatinib and associated healthcare costs. Pharmacoeconomics 2007;25:125-30
   Web of Science ®Google Scholar
• Tsang J, Rudychev I, Pescatore SL. Prescription compliance and persistency in chronic myelogenous leukemia (CML) and gastrointestinal stromal tumor (GIST) patients (patients) on imatinib (IM). Paper presented at: 2006 ASCO Annual Meeting. J Clin Oncol 2006;24(18S):6119
   Google Scholar
• Adamson D, Chang S, Hansen Leigh. White Paper: Health Research Data for the Real World: The MarketScan Databases. Thomson Healthcare, January 2008
   Google Scholar
• Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol 1992;45:613-19
   PubMed Web of Science ®Google Scholar
• Sikka R, Xia F, Aubert RE. Estimating medication persistency using administrative claims data. Am J Manag Care 2005;11:449-57
   PubMed Web of Science ®Google Scholar
• Bureau of Labor Statistics. Measuring Price Change for Medical Care in CPI. Accessed online at http://www.bls.gov/cpi/cpifact4.htm, last accessed on 6/12/09
   Google Scholar
• Manning WG. The logged dependent variable, heteroscedasticity, and the retransformation problem. J Health Econ 1998;17:283-95
   PubMed Web of Science ®Google Scholar
• Manning WG and Mullahy J. Estimating log models: to transform or not to transform?. J Health Econ 2001;20:461-94
   PubMed Web of Science ®Google Scholar
• Mullahy J. Much ado about two: reconsidering retransformation and the two-part model in health econometrics. J Health Econ 1998;17:247-81
   PubMed Web of Science ®Google Scholar
• Sackett DL, Haynes RB. Compliance With Therapeutic Regimens. Baltimore, MD: The Johns Hopkins University Press, 1976
   Google Scholar
• Blackwell B. The drug defaulter. Clin Pharmacol Ther 1972;13:841-8
   PubMed Web of Science ®Google Scholar
• Lebovits AH, Strain JJ, Schleifer SJ, et al. Patient noncompliance with self-administered chemotherapy. Cancer 1990;65:17-22
   PubMed Web of Science ®Google Scholar
• Greenberg RN. Overview of patient compliance with medication dosing: a literature review. Clin Ther 1984;6:592-9
   PubMed Web of Science ®Google Scholar
• Kane, S. Just a spoonful of sugar helps the medicine go down … If only it was that simple! Nonadherence in inflammatory bowel disease. Am J Gastroenterol. 2007;102:1427-8
   PubMed Web of Science ®Google Scholar
• Osterberg L, Blaschke T. Adherence to medication. N Engl J Med 2005;353:487-97
   PubMed Web of Science ®Google Scholar
• Becker MH, Maiman LA. Sociobehavioral determinants of compliance with health and medical care recommendations. Med Care 1975;13:1024
   Web of Science ®Google Scholar
• Becker MH. Sociobehavioral determinants of compliance. In: Sackett DL, Haynes RB, eds. Compliance With Therapeutic Regimens. Baltimore, MD: Johns Hopkins University Press, 1976:40-50
   Google Scholar